source
- BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spellAfter a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity. BlossomHill Therapeutics and Latigo have filed to list on Nasdaq,…
- Dimerix acquires Mission's phase-2 ready AKI drug in $292 million dealDimerix announced it has acquired the acute kidney injury candidate MTX652 from Mission Therapeutics in a deal valued at up to $292 million, including a $5 million upfront payment. Mission had com…